<DOC>
	<DOCNO>NCT02598687</DOCNO>
	<brief_summary>Open-label , single-center phase 1 study investigational agent TH-302 standard chemoradiotherapy 3+3 dose escalation design 3 dose level .</brief_summary>
	<brief_title>Testing TH-302 , Combination With Preoperative Chemoradiotherapy , Esophageal Cancer .</brief_title>
	<detailed_description>Rationale : Neoadjuvant chemoradiotherapy follow surgery remain standard care esophageal cancer patient . Both limit local response well distant metastasis common cause treatment failure . Combining TH-302 chemo-radiotherapy may improve outcome : - Direct cytotoxic effect TH-302 hypoxic cell primary tumor without enhance normal tissue toxicity . - Increase sensitivity primary tumor chemo-radiotherapy decrease hypoxic fraction . - A bystander cytotoxic effect TH-302 normoxic cell adjacent hypoxic cell primary tumor . - A potential cytotoxic effect micro-metastasis . Objective : Primary objective • To determine Maximum Tolerated Dose ( MTD ) TH-302 combine chemoradiotherapy ( 23 x 1.8 Gy combination Carboplatin Paclitaxel ) patient distal esophageal esophago-gastric junction adenocarcinoma , consequently find recommended phase II dose ( RP2D ) . Secondary objective - To explore prognostic predictive value outcome repeat hypoxia PET/CT-scan baseline administration TH-302 ( start RCT ) . - To determine presence anti-tumor activity TH-302 administration . - To explore relationship tumor hypoxia detect HX4 PET/CT-scans serum biomarker expression : CAIX Osteopontin expression . Study design : Open-label , single-center phase 1 study investigational agent TH-302 standard chemoradiotherapy 3+3 dose escalation design 3 dose level . Number patient : 9 to18 . For 3 dose step , 3 6 patient include .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically proven adenocarcinoma esophagus Age &gt; 18 year UICC T24 N02 M0 , potentially resectable disease Patient discuss tumour board ( multidisciplinary team meeting ) No evident tumor invasion nearby region like aorta trachea WHO performance status 02 Less 10 % weight loss past 6 month Laboratory requirement within 7 day prior enrollment ( start chemoradiotherapy ) : Haematology : haemoglobin &gt; 10g/dl absolute neutrophil ≥ 1.5 x 109/L platelet ≥ 100x109/L Biochemistry : bilirubin within institutional normal limit AST ( SGOT ) /ALT ( SGPT ) ≤ 2.5 institutional upper limit Creatinine clearance ≥ 60 ml/min Willing able comply study prescriptions No history prior thoracic radiotherapy No severe chronic obstructive pulmonary disease hypoxemia opinion investigator physiological state lead hypoxemia Women pregnant lactate No know infection HIV , hepatitis B C active infection Normal ECG careful evaluation QT/QTc Have give write informed consent patient registration Recent ( &lt; 3 month ) severe cardiac disease ( arrhythmia , congestive heart failure , infarction ) Patients difficult peripheral intravenous access History prior thoracic radiotherapy severe chronic obstructive pulmonary disease hypoxemia opinion investigator physiological state lead hypoxemia Women pregnant lactate Known infection HIV , hepatitis B C active infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>